Scope of the New Requirements

Under the decree, software-based medical devices are categorized into the following groups:

  • Software as a Medical Device (SaMD): Standalone software intended for one or more medical purposes that does not form part of the hardware of another medical device. Examples include applications for glucose monitoring, medical image analysis, and remote patient monitoring.
  • Software in a Medical Device (SiMD): Software embedded in and forming part of a medical device, which controls its operation or provides specific functions. Examples include software embedded in MRI, CT, ultrasound, ventilator, and pacemaker systems.
  • AI-enabled Medical Devices (AIMD): Medical devices that incorporate AI technologies to analyze health data, identify clinically relevant patterns, and generate information, predictions, classifications, or recommendations for medical purposes.

Key Regulatory Requirements for Manufacturers and Distributors

The decree introduces several technical and operational requirements that manufacturers and distributors should consider when preparing for marketing authorization and maintaining regulatory compliance.

1. Software Verification and Validation Documentation

Manufacturers must prepare software verification and validation documentation based on the software development lifecycle, in accordance with IEC 62304 or another equivalent recognized standard.

The documentation should demonstrate that the software meets its design requirements and user needs, and should include information on:

  • Software version and traceability;
  • Change control and configuration management;
  • Interoperability and compatibility;
  • Cybersecurity and risk mitigation; and
  • Verification and validation test results.

Where the tested software version differs from the version submitted for registration, a version comparison and justification must be provided. Additional validation may be required if significant changes could affect product safety, performance, or intended use.

The marketed software version must also be clearly identified on the product label and/or software interface.

2. Additional Requirements for AI and Machine Learning Medical Devices

For medical devices incorporating AI or machine learning (AI/ML), the registration documentation must provide further details regarding the design, development, validation, and control of the AI system.

The required information includes:

Dataset:

  • Input data types and sources;
  • Dataset size, composition, and characteristics;
  • Dataset preparation, annotation, and separation into training, validation, and testing datasets;

AI Model

  • AI model selection, architecture, and limitations;
  • Performance evaluation results, including relevant metrics such as accuracy, confusion matrix, and Area Under the Curve (AUC);

Performance Evaluation and Clinical Evaluation

  • Verification and validation protocols and reports;
  • Performance parameters such as diagnostic accuracy, sensitivity, specificity, and reproducibility as supporting evidence
  • Clinical performance evidence

Deployment

  • Deployment, monitoring, and software version management.

For AI systems that use continuous machine learning, manufacturers must also establish mechanisms for anomaly detection, dataset integrity, version control, traceability of learning processes, and continuous validation.

For products using Generative AI or Large Language Models (LLMs), additional documentation must address output control, hallucination risk mitigation, usage limitations, and evaluation of the consistency and accuracy of generated medical information.

3. Local Clinical Validation for Certain Imported Software-Based Medical Devices

The decree introduces local clinical validation requirements for certain imported software-based medical devices to demonstrate that their safety, performance, and clinical benefits are appropriate for the target population in Indonesia.

This requirement applies to imported software-based medical devices that:

  • Have undergone further development and/or retraining using data representative of the Indonesian population; and/or
  • Incorporate medium- to high-risk AI technology, particularly for diagnosis, screening, or clinical decision-making purposes.

Local clinical validation may be conducted at hospitals, universities, accredited laboratories, or relevant technical implementation units under the Ministry of Health.

Importantly, local clinical validation may be conducted in parallel with the marketing authorization application by initially submitting the manufacturer's clinical and performance evidence. However, the local clinical validation results must be submitted within a maximum of one year after the marketing authorization is issued.

Apply now!

By identifying the applicable requirements early and strengthening software documentation, quality management systems, and clinical evidence, manufacturers and distributors can better prepare for the marketing authorization of software-based medical devices in Indonesia. Qualtech Consulting Corporation provides regulatory support for medical device manufacturers and distributors, including product classification, registration planning, technical documentation review, software verification and validation assessment, and regulatory compliance strategy. As the regulatory framework continues to develop, staying in touch with Qualtech can help you keep up with the latest requirements and prepare for the changes ahead.

Qualtech has been a trusted partner for medical device manufacturers for over 26+ years. Whether you're a local startup or an international player, we empower your devices to enhance lives.

Contact us to unlock your medical device potential.

Reference

1. Ministry of Health of the Republic of Indonesia, Minister of Health Decree No. HK.01.07/MENKES/951/2026 concerning Guidelines for Marketing Authorization of Software-Based Medical Devices, dated 7 September 2026.

Teilen: